Canariabio Inc.

This study tests a combination of four drugs (oregovomab, bevacizumab, paclitaxel, carboplatin) in adults with recurrent ovarian cancer that has a specific genetic profile (BRCA-normal). The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 54…

This study tests whether adding an immunotherapy drug called oregovomab to standard chemotherapy works better than chemotherapy alone for people with advanced ovarian, fallopian tube, or peritoneal cancer. About 88 newly diagnosed adults will receive either the combo or chemo plu…

This large, late-stage study is testing whether adding an immunotherapy drug called oregovomab to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer without their cancer getting worse. About 615 participants who have already…

This study is testing whether adding an experimental drug called oregovomab to an existing cancer drug, niraparib, can help control recurrent ovarian cancer. It will involve about 10 women whose cancer returned but initially responded well to platinum-based chemotherapy. The main…